Tech Center 1600 • Art Units: 1631 1633 1643 1651
This examiner grants 51% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19041656 | METHODS OF USING COMPOSITIONS COMPRISING SBI DOMAINS | Final Rejection | Helix Nanotechnologies Inc |
| 17778064 | METHOD FOR PROVIDING IMMUNE CELLS WITH ENHANCED FUNCTION | Final Rejection | CARTHERICS PTY. LTD. |
| 18823429 | COMPOSITIONS AND METHODS OF GENOME EDITING | Non-Final OA | EPIGENIC THERAPEUTICS PTE, LTD. |
| 18406066 | FANZORS ARE RNA-GUIDED NUCLEASES ENCODED IN EUKARYOTIC GENOMES | Final Rejection | Massachusetts Institute of Technology |
| 18163253 | Methods and Compositions to Target and Treat Macrophages | Non-Final OA | Massachusetts Institute of Technology |
| 17865375 | Programmable Modification of DNA | Non-Final OA | Massachusetts Institute of Technology |
| 17580190 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 18372374 | METHOD OF PRODUCING A CELL POPULATION COMPRISING AN AMNION-DERIVED MESENCHYMAL STEM CELL | Non-Final OA | KANEKA CORPORATION |
| 17630774 | CYTOSINE BASE-EDITING COMPOSITION AND USE OF SAME | Final Rejection | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) |
| 18484667 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | Non-Final OA | THE TEXAS A&M UNIVERSITY SYSTEM |
| 17756104 | LARGE-SCALE COMBINED CAR TRANSDUCTION AND CRISPR GENE EDITING OF B CELLS | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17755887 | LARGE-SCALE COMBINED CAR TRANSDUCTION AND CRISPR GENE EDITING OF NK CELLS | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17934501 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | Final Rejection | Baylor College of Medicine |
| 18368130 | Rat models for CMT2A that develop a progressive neuropathy | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17759905 | COMPOSITIONS USEFUL FOR TREATING GM1 GANGLIOSIDOSIS | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18980456 | Targeted CRISPR Delivery Platforms | Final Rejection | University of Massachusetts |
| 18049724 | COMPLEXES FOR GENE DELETION AND EDITING | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 18036488 | SALICYLIC ACID-INDUCIBLE GENE EXPRESSION COMPOSITIONS AND SYSTEMS FOR CELLS | Non-Final OA | UNIVERSITY OF HOUSTON SYSTEM |
| 17911041 | A MIXTURE OF MRNA TO ENHANCE THE POTENCY OF DENDRITIC CELLS | Non-Final OA | Vrije Universiteit Brussel |
| 17954674 | MODIFIED GRAFTS | Non-Final OA | Musculoskeletal Transplant Foundation |
| 18486731 | GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | Non-Final OA | FIGENE, LLC |
| 18003093 | METHODS OF GENERATING AN ACTIVATION INDUCIBLE EXPRESSION SYSTEM IN IMMUNE CELLS | Non-Final OA | St. Jude Children's Research Hospital, Inc. |
| 18613605 | PROTEOLIPID VESICLES FORMULATED WITH FUSION ASSOCIATED SMALL TRANSMEMBRANE PROTEINS | Final Rejection | ENTOS PHARMACEUTICALS INC. |
| 16098918 | DNA Monoclonal Antibodies Targeting IL-6 and CD126 | Final Rejection | The Wistar Institute of Anatomy and Biology |
| 18302962 | SYNTHETIC ADENOVIRUSES TARGETING BONE TISSUE AND USES THEREOF | Non-Final OA | Salk Institute for Biological Studies |
| 18176500 | RECOMBINANT DGKK GENE FOR FRAGILE X SYNDROME GENE THERAPY | Non-Final OA | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE |
| 17742724 | HYBRID NUCLEIC ACID MOLECULES AND THEIR USE | Final Rejection | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE |
| 18271715 | METHOD FOR CULTURING HUMAN HEPATIC PARENCHYMAL CELL, CULTURED HUMAN HEPATIC PARENCHYMAL CELL, CULTURE MEDIUM AND METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING CULTURE SUPERNATANT OF HUMAN HEPATIC NONPARENCHYMAL CELL | Non-Final OA | JSR CORPORATION |
| 17674378 | INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY | Final Rejection | The U.S.A., as Represented by the Secretary, Department of Health and Human Services |
| 18158310 | CELL | Non-Final OA | AUTOLUS LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy